Critical reviews in oncology/hematology · 2021
The use of bolus in postmastectomy radiation therapy for breast cancer: A systematic review.
СтатьяСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dahn Hannah M, Boersma Liesbeth J, de Ruysscher Dirk, Meattini Icro, Offersen Birgitte V, Pignol Jean-Philippe, Aristei Cynthia, Belkacemi Yazid, Benjamin Dori, Bese Nuran, Coles Charlotte E, Franco Pierfrancesco, Ho Alice, Hol Sandra, Jagsi Reshma, Kirby Anna M, Marrazzo Livia, Marta Gustavo N, Moran Meena S, Nichol Alan M, Nissen Henrik D, Strnad Vratislav, Zissiadis Yvonne E, Poortmans Philip, Kaidar-Person Orit
Аннотация
PURPOSE: Post mastectomy radiation therapy (PMRT) reduces locoregional recurrence (LRR) and breast cancer mortality for selected patients. Bolus overcomes the skin-sparing effect of external-beam radiotherapy, ensuring adequate dose to superficial regions at risk of local recurrence (LR). This systematic review summarizes the current evidence regarding the impact of bolus on LR and acute toxicity in the setting of PMRT.
RESULTS: 27 studies were included. The use of bolus led to higher rates of acute grade 3 radiation dermatitis (pooled rates of 9.6% with bolus vs. 1.2% without). Pooled crude LR rates from thirteen studies (n = 3756) were similar with (3.5%) and without (3.6%) bolus.
CONCLUSIONS: Bolus may be indicated in cases with a high risk of LR in the skin, but seems not to be necessary for all patients. Further work is needed to define the role of bolus in PMRT.
RESULTS: 27 studies were included. The use of bolus led to higher rates of acute grade 3 radiation dermatitis (pooled rates of 9.6% with bolus vs. 1.2% without). Pooled crude LR rates from thirteen studies (n = 3756) were similar with (3.5%) and without (3.6%) bolus.
CONCLUSIONS: Bolus may be indicated in cases with a high risk of LR in the skin, but seems not to be necessary for all patients. Further work is needed to define the role of bolus in PMRT.